Christian Kanstrup
Chief Executive Officer presso EVAXION BIOTECH A/S
Patrimonio netto: 47 090 $ in data 31/03/2024
Profilo
Christian Kanstrup is currently the Chief Executive Officer at Evaxion Biotech A, Director at NNIT A, and Chairman at Mediq Holding Danmark ApS.
He is also a Director at Novo Nordisk Haemophilia Foundation.
In the past, he worked as a Director at FastPassCorp A, Director at Glycom A, and SVP-Strategy, Access & Marketing at Novo Nordisk A.
He has a graduate degree from the University of Copenhagen and a graduate degree from the International Institute for Management Development.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
NNIT A/S
0.01% | 31/12/2023 | 3 000 ( 0.01% ) | 47 090 $ | 31/03/2024 |
Posizioni attive di Christian Kanstrup
| Società | Posizione | Inizio |
|---|---|---|
| NNIT A/S | Director/Board Member | 08/03/2018 |
| EVAXION BIOTECH A/S | Chief Executive Officer | 29/08/2023 |
| Novo Nordisk Haemophilia Foundation | Director/Board Member | - |
Mediq Holding Danmark ApS
 Mediq Holding Danmark ApS Financial ConglomeratesFinance Part of Mediq BV, Mediq Holding Danmark ApS is a Danish company that functions as an investment holding company. The private company is based in Brøndby, Denmark. The company was founded in 2010 by Jesper Schultz Larsen. The CEO is Katrine Bjarkov Benthien. | Chairman | - |
Precedenti posizioni note di Christian Kanstrup
| Società | Posizione | Fine |
|---|---|---|
| FASTPASSCORP A/S | Director/Board Member | 02/03/2019 |
Glycom A/S
 Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Director/Board Member | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Formazione di Christian Kanstrup
| University of Copenhagen | Graduate Degree |
| International Institute for Management Development | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| FASTPASSCORP A/S | Technology Services |
| NNIT A/S | Technology Services |
| EVAXION BIOTECH A/S | Health Technology |
| Aziende private | 3 |
|---|---|
Glycom A/S
Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Health Technology |
| Novo Nordisk Haemophilia Foundation | |
Mediq Holding Danmark ApS
Mediq Holding Danmark ApS Financial ConglomeratesFinance Part of Mediq BV, Mediq Holding Danmark ApS is a Danish company that functions as an investment holding company. The private company is based in Brøndby, Denmark. The company was founded in 2010 by Jesper Schultz Larsen. The CEO is Katrine Bjarkov Benthien. | Finance |
- Borsa valori
- Insiders
- Christian Kanstrup
